Literature DB >> 33882273

New tetrahydroisoquinoline-based D3R ligands with an o-xylenyl linker motif.

Pierpaolo Cordone1, Hari K Namballa2, Bryant Muniz2, Rajat K Pal3, Emilio Gallicchio4, Wayne W Harding5.   

Abstract

The effect of rigidification of the n-butyl linker region of tetrahydroisoquinoline-containing D3R ligands via inclusion of an o-xylenyl motif was examined in this study. Generally, rigidification with an o-xylenyl linker group reduces D3R affinity and negatively impacts selectivity versus D2R for compounds possessing a 6-methoxy-1,2,3,4,-tetrahydroisoquinolin-7-ol primary pharmacophore group. However, D3R affinity appears to be regulated by the primary pharmacophore group and high affinity D3R ligands with 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline primary pharmacophore groups were identified. The results of this study also indicate that D3R selectivity versus the σ2R is dictated by the benzamide secondary pharmacophore group, this being facilitated with 4-substituted benzamides. Compounds 5s and 5t were identified as high affinity (Ki < 4 nM) D3R ligands. Docking studies revealed that the added phenyl ring moiety interacts with the Cys181 in D3R which partially accounts for the strong D3R affinity of the ligands.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D(3)R; Docking; Dopamine receptor; Tetrahydroisoquinoline; σ(2)R

Mesh:

Substances:

Year:  2021        PMID: 33882273      PMCID: PMC8165021          DOI: 10.1016/j.bmcl.2021.128047

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.940


  27 in total

1.  Neuroprotective effects of high affinity Σ1 receptor selective compounds.

Authors:  Robert R Luedtke; Evelyn Perez; Shao-Hua Yang; Ran Liu; Suwanna Vangveravong; Zhude Tu; Robert H Mach; James W Simpkins
Journal:  Brain Res       Date:  2011-12-31       Impact factor: 3.252

Review 2.  Recent advances in the development of dopamine D3 receptor antagonists: a medicinal chemistry perspective.

Authors:  Fabrizio Micheli
Journal:  ChemMedChem       Date:  2011-03-18       Impact factor: 3.466

Review 3.  The dopamine D3 receptor, a quarter century later.

Authors:  Pierre Sokoloff; Bernard Le Foll
Journal:  Eur J Neurosci       Date:  2016-10-03       Impact factor: 3.386

4.  Comparative evaluation of 4 and 6-carbon spacer conformationally flexible tetrahydroisoquinolinyl benzamide analogues for imaging the sigma-2 receptor status of solid tumors.

Authors:  Iljung Lee; Brian P Lieberman; Shihong Li; Catherine Hou; Mehran Makvandi; Robert H Mach
Journal:  Nucl Med Biol       Date:  2016-08-09       Impact factor: 2.408

5.  Effect of structural modification in the amine portion of substituted aminobutyl-benzamides as ligands for binding σ1 and σ2 receptors.

Authors:  Kuo-Hsien Fan; John R Lever; Susan Z Lever
Journal:  Bioorg Med Chem       Date:  2011-02-12       Impact factor: 3.641

Review 6.  The potential role of dopamine D₃ receptor neurotransmission in cognition.

Authors:  Shinichiro Nakajima; Philip Gerretsen; Hiroyoshi Takeuchi; Fernando Caravaggio; Tiffany Chow; Bernard Le Foll; Benoit Mulsant; Bruce Pollock; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2013-06-20       Impact factor: 4.600

7.  Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.

Authors:  Amy Hauck Newman; Thijs Beuming; Ashwini K Banala; Prashant Donthamsetti; Katherine Pongetti; Alex LaBounty; Benjamin Levy; Jianjing Cao; Mayako Michino; Robert R Luedtke; Jonathan A Javitch; Lei Shi
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

8.  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.

Authors:  Amy Hauck Newman; Jianjing Cao; Christina J Bennett; Michael J Robarge; Rebekah A Freeman; Robert R Luedtke
Journal:  Bioorg Med Chem Lett       Date:  2003-07-07       Impact factor: 2.823

Review 9.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

10.  Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation.

Authors:  Catherine Hou; Chia-Ju Hsieh; Shihong Li; Hsiaoju Lee; Thomas J Graham; Kuiying Xu; Chi-Chang Weng; Robert K Doot; Wenhua Chu; Subhasish K Chakraborty; Laura L Dugan; Mark A Mintun; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2017-12-03       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.